David A. Piacquad's most recent trade in AMGEN Inc. was a trade of 6,159 Nqso (Right to Buy) done . Disclosure was reported to the exchange on April 30, 2021.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Amgen | David A. Piacquad | SVP, Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 6,159 | 6,159 | - | - | Nqso (Right to Buy) | |
| Amgen | David A. Piacquad | SVP, Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 709 | 45,146 (0%) | 0% | 0 | Common Stock | |
| Amgen | David A. Piacquad | SVP, Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 239.64 per share. | 30 Apr 2021 | 220 | 44,787 (0%) | 0% | 239.6 | 52,721 | Common Stock |
| Amgen | David A. Piacquad | SVP, Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 239.64 per share. | 30 Apr 2021 | 139 | 45,007 (0%) | 0% | 239.6 | 33,310 | Common Stock |
| Amgen | David A. Piacquad | SVP, Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 255.52 per share. | 27 Apr 2021 | 128 | 44,437 (0%) | 0% | 255.5 | 32,707 | Common Stock |
| Amgen | David A. Piacquad | SVP, Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.42 per share. | 19 Mar 2021 | 991 | 44,565 (0%) | 0% | 244.4 | 242,220 | Common Stock |
| Amgen | David A. Piacquad | SVP, Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 2,648 | 45,504 (0%) | 0% | 0 | Common Stock |